麻豆社

Hjernen og depression

Danish research discovers significant depression-risk interaction between personality and brain chemistry

People walking

By Henrik Larsen


This discovery advances our understanding of the causes of major depressive disorder and indicates the need to target novel therapies. 鈥淭hese could include a combination of psychedelic compounds and psychotherapy,鈥 says head of the Danish research project, Professor Vibe Fr酶kj忙r.

A Danish research team is the first to demonstrate that healthy individuals with a specific brain chemistry and psychological profile have a long-term risk for developing major depressive disorder.

This discovery has just been published in Nature Mental Health, one of the world鈥檚 most important scientific journals. The study was conducted by researchers from Rigshospitalet, University of Copenhagen and Mental Health Services in the Capital Region of Denmark.

The Nature article reveals that otherwise healthy individuals, oblivious to the existence of this threat to their mental health, are at high risk for depression stemming from an interaction between two factors:

Vibe Fr酶kj忙r
Vibe Fr酶kj忙r, professor of neuropsychiatry at the Neurobiology Research Unit at Rigshospitalet and the Mental Health Services, Capital Region of Denmark, and leader of the team behind the Nature article.

Psychologically, a personality profile characterised by high neuroticism, including pronounced anxiety, self-consciousness and a low threshold for enduring stress.

Brain chemistry, involving receptors which mediate the brain鈥檚 internal communication by means of serotonin (serotoni n2A receptor type in particular), a signalling substance.

鈥淲hen these personality and brain chemistry factors are present at the same time in an individual, their long-term risk for major depression increases. This is what we have been able to demonstrate,鈥 explains Fr酶kj忙r, Professor in Neuropsychiatry at the Neurobiology Research Unit (NRU) at Rigshospitalet and Mental Health Services, Capital Region of Denmark. Fr酶kj忙r headed up the team that published the Nature article, and received research funding from the Lundbeck Foundation and Innovation Fund Denmark.

Anjali Sankar
Anjali Sankar, Ph.D. in Psychology and Neuroscience at the Neurobiology Research Unit at Rigshospitalet, is the first author of the Nature article.

This discovery advances our understanding of major depressive disorder, which is very promising,鈥 says Professor Fr酶kj忙r, adding: 

鈥淎nyone can develop depression, and in some cases, it appears to come on with no warning. But the better we understand the complex interactions of psychological and brain chemistry factors underlying depression, the better we鈥檒l be able to treat and prevent this mental disorder. Our discovery also points to the necessity in some cases of being open to 

using new modes of treatment for depression. These could include a combination of psychotherapy and psychedelic compounds such as psilocybin. This is another important finding we made,鈥 explains Fr酶kj忙r.

HOW THE STUDY WAS CONDUCTED

The Nature article is based on brain research data from 131 Danes, who in the period 2000-2008 were recruited as healthy participants for studies at Rigshospitalet. The initial study was approved by the Regional Research Ethics Committee and the Danish Data Protection Agency. Participants, aged 18-81 at enrollment, were recruited through advertised calls and gave informed consent to take part in the studies which involved PET and MRI brain scans as well as personality testing. The brain scans were used to assess the distribution of the participants鈥 serotonin 2A receptor brain binding, while personality tests evaluated neuroticism levels.

Following approval from the Danish Health Data Authority鈥檚 Research Services, researchers conducted a registry-based follow-up study. This allowed them to link the original PET and personality research data to relevant health registries, which provided longitudinal health information. To protect participant privacy, the data were de-identified and anonymized by the data controllers at Statistics Denmark, ensuring that individuals could not be identified while still allowing researchers to track whether participants were later hospitalised with depression, had been diagnosed with a major depressive disorder, or had been prescribed antidepressants. By examining all these factors in all 131 study participants for a period of up to 19 years, the scientists were finally able to present scientific evidence for the existence of the distinct risk profile.

The original study was conducted at the Lundbeck Foundation Center for Integrated Molecular Brain Imaging (Cimbi), Neurobiology Research Unit (NRU), Rigshospitalet. Cimbi was established in 2006 via a Lundbeck Foundation grant.

WHO ARE AT RISK?

The distinct depression-risk link between personality traits and brain chemistry discovered by the Danish research team raises the question: How many people have this profile?

Anyone can develop depression, and in some cases, it appears to come on with no warning. But the better we understand the complex interactions of psychological and brain chemistry factors underlying depression, the better we鈥檒l be able to treat and prevent this mental disorder. 
Vibe Fr酶kj忙r

鈥淭he study does not set out to estimate this number in the Danish population, but it offers important insights into a specific profile that is associated with heightened risk for depression- a finding we hope will take us one step closer to understanding the disorder鈥檚 complex pathophysiology.鈥 says Anjali Sankar, from the Neurobiology Research Unit (NRU) at Rigshospitalet. Sankar who holds a PhD in psychology and neuroscience, is the first author of the Nature article, and spearheaded the analyses that resulted in discovery of the special risk profile.

NOVEL THERAPIES FOR DEPRESSION

Depression research has long-since established that the 2A serotonin receptors featured in the recent Nature article are involved in depression. It is also known that various psychedelic compounds such as psilocybin, which is present in a number of 鈥榤agic鈥 mushrooms, such as the liberty cap (Psilocybe semilanceata) can beneficially stimulate these receptors as part of antidepressant therapy sessions. For this reason, research is ongoing worldwide, including in Denmark, on combinations of psychotherapy and medicinal treatment with psychedelic compounds such as psilocybin. This is carried out in controlled studies supervised by medical doctors and clinical psychologists. Another psychedelic compound under investigation in trials of antidepressant therapy is LSD.

We studied a total of 131 healthy individuals who underwent brain scans and psychometric testing, with a subsequent 19 years of follow up in Danish health registries. In addition to the specific risk profile that is associated with developing a future depressive episode, we found that the risk for depression measured over the entire period was 24 percent in women as opposed to seven percent in men. This reflects the reality we鈥檙e already familiar with from depression studies: that women are far more likely than men to be diagnosed with major depressive disorder,鈥 says Sankar. 

The figure illustrates the distribution of 5-HT2AR binding in the healthy human brain, imaged using [18F]altanserin Positron Emission Tomohraphy.
The figure illustrates the distribution of 5-HT2AR binding in the healthy human brain, imaged using [18F]altanserin Positron Emission Tomohraphy.

But now that the risk profile among healthy individuals for being diagnosed with severe depression has been established, it should be possible to put that knowledge to use in devising a form of screening test, as a kind of early warning of future depression.

Although that is an interesting idea, it is not exactly possible to do in practice, as Professor Fr酶kj忙r explains:

鈥淎s I see it, the best thing is to try to live naturally, making the most of life without harm to our mental health. And the aim should be to concentrate on stress management, and coming to terms with the inevitability and necessity of occasional adversity in life.鈥

Supported by the Lundbeck Foundation

The Neurobiology Research Unit at Rigshospitalet received a research grant of DKK 40 million from the Lundbeck Foundation in 2019 for the project, which also includes researchers from the University of Copenhagen and the Mental Health Services, Capital Region of Denmark. The main aim is to identify factors that can predict how patients with epilepsy or depression will respond to medical treatment, thereby improving the effectiveness of the treatment. Read more about the project:

Read the full article in Nature Mental Health: